RLYB116
Complement-mediated diseases
Phase 1Confirmatory PK/PD study ongoing
Key Facts
Indication
Complement-mediated diseases
Phase
Phase 1
Status
Confirmatory PK/PD study ongoing
Company
About Rallybio
Rallybio is a clinical-stage biotech committed to transforming the lives of millions of patients with rare diseases by advancing innovative therapies in complement dysregulation and hematology. The company leverages a team with extensive drug development experience, having contributed to over 30 drug approvals, and maintains a global network of industry and academic partners. Its disciplined approach aims to translate scientific breakthroughs into life-changing treatments, with a lead C5 inhibitor program (RLYB116) in confirmatory PK/PD studies.
View full company profileTherapeutic Areas
Other Complement-mediated diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Pozelimab | Regeneron Pharmaceuticals | Phase 2/3 |
| ARGX-117 | Argenx | Phase 1/2 |
| ANX009 | Annexon | Preclinical |
| ADX-096 | Q32 Bio | Discovery/Preclinical |
| C3d mAb fusions | Q32 Bio | Discovery/Preclinical |
| Complement-targeting nanobodies | Q32 Bio | Discovery/Preclinical |